Overview

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced ovarian epithelial cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
New York University School of Medicine
NYU Langone Health
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Topotecan
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed advanced ovarian epithelial carcinoma, regardless of quantity
of disease post-surgery

- Stage IC, II, III, or IV

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- SGOT no greater than 3 times upper limit of normal

- Bilirubin no greater than 2.0 mg/dL

- No clinically significant hepatic disorder

Renal:

- Creatinine no greater than 1.5 mg/dL OR

- Creatinine clearance greater than 60 mL/min

- No clinically significant renal disorder

Cardiovascular:

- No clinically significant cardiovascular condition

Other:

- Normal GI function allowing reliable administration of oral medication

- No active infection requiring systemic medical therapy within past week

- No other clinically significant medical condition (e.g., endocrine/metabolic or
autoimmune disorder)

- No other prior malignancy within the past 5 years except nonmelanoma skin cancer or
carcinoma in situ of the cervix

- No dementia or altered mental status that would preclude consent

- Not pregnant

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy for ovarian epithelial carcinoma

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior radiotherapy for ovarian epithelial carcinoma

Surgery:

- See Disease Characteristics